Apparatus and method for providing information on parkinson's disease using neuromelanin image
Inventors
PARK, Seongbeom • Song, Soo Hwa
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-11207019-B1
Publication Date
2021-12-28
Expiration Date
Abstract
The Parkinson's disease information providing apparatus using a neuromelanin image according to an aspect of the present disclosure includes an image receiving unit which acquires an MRI image obtained by capturing a brain of a patient; an image preprocessing unit which preprocesses the acquired MRI image to observe the neuromelanin region used as an image bio marker of the Parkinson's disease; an image processing unit which analyzes the preprocessed MRI image to classify a first image including the neuromelanin region and detects the neuromelanin region from the classified first image; and an image analyzing unit which diagnoses whether the patient has the Parkinson's disease by analyzing whether the detected the neuromelanin region is normal.
Core Innovation
The invention is a Parkinson's disease information providing apparatus using a neuromelanin image. The apparatus includes an image receiving unit that acquires an MRI image obtained by capturing a brain of a patient, and an image preprocessing unit that preprocesses the acquired MRI image to observe a neuromelanin region used as an image bio marker of Parkinson's disease.
An image processing unit analyzes the preprocessed MRI image to classify a first image including the neuromelanin region and detects the neuromelanin region from the classified first image. An image analyzing unit analyzes the detected neuromelanin region to determine information of the patient related to Parkinson's disease, and the image processing unit calculates a volume of the neuromelanin region based on the first image.
The invention also includes a system that increases a probability of successful clinical trials by screening a patient group having Parkinson's disease. The system uses the Parkinson's disease information providing apparatus and includes an image receiving unit, an image preprocessing unit, an image processing unit, an image analyzing unit, and a central management unit and/or a server.
The image receiving unit acquires MRI images obtained by capturing brains of a plurality of patients in a clinical trial experimental candidate group, and the central management unit and/or the server uses a clinical trial result for a first patient to demonstrate drug efficacy.
Claims Coverage
The relevant independent claims are directed to two inventive features: a Parkinson's disease information providing apparatus and a clinical trial screening system. Across the claims, the core inventive features include neuromelanin-region detection from MRI, neuromelanin-region volume calculation, use of that volume to determine Parkinson's disease-related patient information, and a clinical-trial screening and central-server reporting loop in the system claim.
Neuromelanin image-based Parkinson's disease information providing apparatus
A Parkinson's disease information providing apparatus using a neuromelanin image, comprising an image receiving unit acquiring an MRI image obtained by capturing a brain of a patient, an image preprocessing unit preprocessing the acquired MRI image to observe a neuromelanin region used as an image bio marker of Parkinson's disease, an image processing unit analyzing the preprocessed MRI image to classify a first image including the neuromelanin region and to detect the neuromelanin region, and an image analyzing unit analyzing the detected neuromelanin region to determine information of the patient related to Parkinson's disease.
Neuromelanin-region volume calculation for determining Parkinson's disease-related patient information
The image processing unit calculates a volume of the neuromelanin region based on the first image, and the image analyzing unit determines information of the patient related to Parkinson's disease using the calculated volume of the neuromelanin region.
Clinical trial success probability increase by screening using neuromelanin-region detection
A system which increases a probability of successful clinical trials by screening a patient group having Parkinson's disease using a Parkinson's disease information providing apparatus including an image receiving unit, an image preprocessing unit, an image processing unit, and an image analyzing unit, together with a central management unit and/or a server, wherein the image receiving unit acquires MRI images obtained by capturing brains of a plurality of patients in a clinical trial experimental candidate group, and the central management unit and/or the server uses a clinical trial result for a first patient to demonstrate drug efficacy.
Patient-group screening output transmitted to a central management unit and/or server
The image analyzing unit analyzes the detected neuromelanin region to determine information of the patient related to Parkinson's disease and transmits at least one information about a first patient which satisfies a first condition, among the plurality of patients, to the central management unit and/or the server based on the information of the patient.
Overall, the claim set covers an MRI-based neuromelanin image workflow that detects a neuromelanin region, calculates a neuromelanin-region volume, and uses that volume to determine Parkinson's disease-related patient information, and further covers a system that uses this patient information to screen a Parkinson's disease patient group to increase the probability of successful clinical trials, with results used to demonstrate drug efficacy.
Stated Advantages
Increases a probability of successful clinical trials by screening a patient group having Parkinson's disease.
Documented Applications
Screening a patient group having Parkinson's disease using MRI-based neuromelanin information to increase the probability of successful clinical trials, including transmitting information about a first patient to a central management unit and/or server for use with clinical trial results to demonstrate drug efficacy.
Interested in licensing this patent?